Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases

• Published in: Brain tumor pathology Vol. 26; no. 2; pp. 51 - 57
• Main Authors: Fukushima, Shintaro, Terasaki, Mizuhiko, Sakata, Kiyohiko, Miyagi, Naohisa, Kato, Seiya, Sugita, Yasuo, Shigemori, Minoru
• Format: Journal Article
• Language: English
• Published: Japan Springer Japan 01.10.2009; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Analysis of Variance; Cancer Research; Embolization; Eosine Yellowish-(YS); Female; Hematoxylin; Histones - metabolism; Humans; Immunohistochemistry; Ki-67 Antigen - metabolism; Male; Medicine; Medicine & Public Health; Meningeal Neoplasms - diagnosis; Meningeal Neoplasms - metabolism; Meningeal Neoplasms - pathology; Meningioma - diagnosis; Meningioma - metabolism; Meningioma - pathology; Middle Aged; Mitosis; Mitotic Index - methods; Neurology; Neurosurgery; Oncology; Original Article; Pathology; Phosphorylation; Sensitivity and Specificity; Feeder embolization; Mitotic figure; MIB-1; PHH3; Meningioma
• ISSN: 1433-7398; 1861-387X
• DOI: 10.1007/s10014-009-0249-9

According to current World Health Organization (WHO) criteria, counting mitotic figures (MF), which is equal to the mitotic index (MI), on paraffin sections stained with hematoxylin and eosin (HE) is one of the recognized classification methods for meningiomas. However, it is not always easy to find the area of highest mitotic activity, and there are different perspectives among pathologists with regard to differentiating MF from non-MF, i.e., which are apoptotic figures and which are crushed or distorted cells. Moreover, there is an issue of overgrading in meningiomas with preoperative feeder embolization. Recently, anti-phosphohistone-H3 (PHH3) antibody has been reported as a mitosis-specific marker for meningioma grading. In this study, we attempted PHH3 immunostaining for our meningioma cases and verified not only the sensitivity of PHH3 immunostaining but also that of its usefulness in grading meningiomas. Forty-five initial histologically confirmed meningiomas (37 benign, 7 atypical, and 1 anaplastic) were reviewed according to current WHO criteria based on counting MF on HE-stained slides. PHH3-immunostained MF were counted in the same way, and the MIB-1 labeling index (LI) was calculated for each sample. PHH3-labeled MF were easily identified and permitted rapid recognition of the areas of highest mitotic activity. As a result, significant increase of PHH3 mitotic index (PHH3-MI) in comparison with HE mitotic index (HE-MI) and strong correlations with HE-MI to PHH3-MI as well as PHH3-MI to MIB-1 LI were demonstrated. Furthermore, no significant differences of PHH3-MI between cases with and without feeder embolization were demonstrated. As such, PHH3 may be a sensitive and useful marker for meningioma grading as based on the MF.